Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...
President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.
COPENHAGEN (Reuters) -Shares of weight-loss drug makers Novo Nordisk and Eli Lilly fell on Friday after U.S. President Donald Trump said that the price of Novo's popular Ozempic treatment ...
Hosted on MSN
Novo Nordisk (NVO) and Eli Lilly (LLY): Weight-Loss Drug Stocks Dip on Trump’s New Price PromiseNovo Nordisk (NVO) and Eli Lilly & Co. (LLY) shares are trending lower in pre-market trading after President Donald Trump said the price of Ozempic, Novo’s top-selling weight-loss and diabetes ...
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Shares of Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are ...
FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo (Reuters) -Eli Lilly's ...
Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the ...
Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two Phase 3 trials for patients with type 2 diabetes, indicating its ...
FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo FILE PHOTO: The Eli Lilly logo is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results